14.67
0.00 (0.00%)
| Penutupan Terdahulu | 14.67 |
| Buka | 14.67 |
| Jumlah Dagangan | 401,621 |
| Purata Dagangan (3B) | 1,098,012 |
| Modal Pasaran | 1,043,600,896 |
| Harga / Jualan (P/S) | 7.67 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Oct 2025 |
| Margin Operasi (TTM) | -276.53% |
| EPS Cair (TTM) | -5.18 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 1,391.60% |
| Nisbah Semasa (MRQ) | 3.58 |
| Aliran Tunai Operasi (OCF TTM) | -282.68 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -201.84 M |
| Pulangan Atas Aset (ROA TTM) | -55.01% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Phathom Pharmaceuticals, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.25 |
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.28% |
| % Dimiliki oleh Institusi | 84.77% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 30 Sep 2025 | 12,466,489 |
| Medicxi Ventures Management (Jersey) Ltd | 30 Sep 2025 | 7,464,572 |
| Carlyle Group Inc. | 30 Sep 2025 | 3,496,808 |
| Ensign Peak Advisors, Inc | 30 Sep 2025 | 2,503,344 |
| Catalys Pacific, Llc | 30 Sep 2025 | 1,167,114 |
| Catalio Capital Management, Lp | 30 Sep 2025 | 1,128,521 |
| Julat 52 Minggu | ||
| Median | 26.00 (77.23%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 31 Oct 2025 | 26.00 (77.23%) | Beli | 13.55 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |